FDA OKs tisotumab vedotin
What happened
The FDA approved the antibody‑drug conjugate tisotumab vedotin for recurrent or metastatic cervical cancer, offering a new treatment where options were limited. The decision highlights the ongoing need for precise diagnostic reporting and biomarker workups when cytology may be the only available tissue source. (curetoday.com)
Why it matters
FDA converted TIVDAK’s accelerated approval (Sep 20, 2021) to full U.S. approval on April 29, 2024 after submission of a supplemental BLA. (fda.gov)) The Phase 3 innovaTV‑301 randomized trial enrolled 502 patients and showed median overall survival of 11.5 months with tisotumab vedotin versus 9.5 months with investigator‑choice chemotherapy (HR ≈0.70), with secondary endpoints of PFS and confirmed ORR also favoring TIVDAK. (nejm.org)) TIVDAK carries a boxed warning for severe ocular toxicity and the label requires an ophthalmic exam (visual acuity and slit‑lamp exam) at baseline, prior to every cycle for the first nine cycles, and adherence to specific premedication and eye‑care measures such as topical corticosteroids, lubricating drops, and cooling eye pads during infusion. (labeling.pfizer.com)) Determination of tumor tissue factor (TF) expression was not required for enrollment in innovaTV‑301 and the U.S. label does not stipulate a companion diagnostic for TF, while the trial protocol allowed submission of fresh or archival tumor samples if a fresh biopsy was not feasible. (tivdakhcp.com)) Across clinical programs, hemorrhage was reported in roughly half of treated cervical‑cancer patients (published pooled figure ~51%), with epistaxis the most common bleeding event, and ocular adverse reactions led to permanent discontinuation in about 6% of patients in the pivotal dataset. (tivdakhcp.com)) The recommended TIVDAK dose is 2.0 mg/kg (maximum 200 mg) IV over 30 minutes every 3 weeks until progression or unacceptable toxicity, and recent guideline listings identify TIVDAK as a preferred second‑ or later‑line option for recurrent/metastatic cervical cancer. (labeling.pfizer.com))
Key numbers
- (curetoday.com) FDA converted TIVDAK’s accelerated approval (Sep 20, 2021) to full U.S.
- approval on April 29, 2024 after submission of a supplemental BLA.
- (labeling.pfizer.com)) Determination of tumor tissue factor (TF) expression was not required for enrollment in innovaTV‑301 and the U.S.
What happens next
- The decision highlights the ongoing need for precise diagnostic reporting and biomarker workups when cytology may be the only available tissue source.
Quick answers
What happened in FDA OKs tisotumab vedotin?
The FDA approved the antibody‑drug conjugate tisotumab vedotin for recurrent or metastatic cervical cancer, offering a new treatment where options were limited. The decision highlights the ongoing need for precise diagnostic reporting and biomarker workups when cytology may be the only available tissue source. (curetoday.com)
Why does FDA OKs tisotumab vedotin matter?
FDA converted TIVDAK’s accelerated approval (Sep 20, 2021) to full U.S. approval on April 29, 2024 after submission of a supplemental BLA. (fda.gov)) The Phase 3 innovaTV‑301 randomized trial enrolled 502 patients and showed median overall survival of 11.5 months with tisotumab vedotin versus 9.5 months with investigator‑choice chemotherapy (HR ≈0.70), with secondary endpoints of PFS and confirmed ORR also favoring TIVDAK. (nejm.org)) TIVDAK carries a boxed warning for severe ocular toxicity and the label requires an ophthalmic exam (visual acuity and slit‑lamp exam) at baseline, prior to every cycle for the first nine cycles, and adherence to specific premedication and eye‑care measures such as topical corticosteroids, lubricating drops, and cooling eye pads during infusion. (labeling.pfizer.com)) Determination of tumor tissue factor (TF) expression was not required for enrollment in innovaTV‑301 and the U.S. label does not stipulate a companion diagnostic for TF, while the trial protocol allowed submission of fresh or archival tumor samples if a fresh biopsy was not feasible. (tivdakhcp.com)) Across clinical programs, hemorrhage was reported in roughly half of treated cervical‑cancer patients (published pooled figure ~51%), with epistaxis the most common bleeding event, and ocular adverse reactions led to permanent discontinuation in about 6% of patients in the pivotal dataset. (tivdakhcp.com)) The recommended TIVDAK dose is 2.0 mg/kg (maximum 200 mg) IV over 30 minutes every 3 weeks until progression or unacceptable toxicity, and recent guideline listings identify TIVDAK as a preferred second‑ or later‑line option for recurrent/metastatic cervical cancer. (labeling.pfizer.com))
